Found: 14
Select item for more details and to access through your institution.
Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Implications of Mutation Profiling in Myeloid Malignancies: PART 2: Myeloproliferative Neoplasms and Other Myeloid Malignancies.
- Published in:
- Oncology (08909091), 2018, v. 32, n. 5, p. e45
- By:
- Publication type:
- Article
Implications of Mutation Profiling in Myeloid Malignancies: PART 1: Myelodysplastic Syndromes and Acute Myeloid Leukemia.
- Published in:
- Oncology (08909091), 2018, v. 32, n. 4, p. e38
- By:
- Publication type:
- Article
Clarifying the Use of Ruxolitinib in Patients With Myelofibrosis.
- Published in:
- Oncology (08909091), 2013, v. 27, n. 7, p. 706
- By:
- Publication type:
- Article
Risk Factors for Disease Progression and Treatment Goals in Polycythemia Vera.
- Published in:
- Clinical Advances in Hematology & Oncology, 2024, v. 22, n. 1, p. 31
- By:
- Publication type:
- Article
Distinguishing Autoimmune Myelofibrosis from Primary Myelofibrosis.
- Published in:
- Clinical Advances in Hematology & Oncology, 2018, v. 16, n. 9, p. 619
- By:
- Publication type:
- Article
Metabolic Effects of JAK1/2 Inhibition in Patients with Myeloproliferative Neoplasms.
- Published in:
- Scientific Reports, 2019, v. 9, n. 1, p. N.PAG, doi. 10.1038/s41598-019-53056-x
- By:
- Publication type:
- Article
Treating accelerated and blast phase myeloproliferative neoplasms: progress and challenges.
- Published in:
- Therapeutic Advances in Hematology, 2023, v. 14, p. 1, doi. 10.1177/20406207231177282
- By:
- Publication type:
- Article
Oral Decitabine/Cedazuridine Is an Effective Ambulatory Therapy for Patients With Myelofibrosis Refractory to JAK2 Inhibitor Therapy.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2024, v. 24, n. 9, p. e314, doi. 10.1016/j.clml.2024.05.012
- By:
- Publication type:
- Article
Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Leukemic Transformation of Myeloproliferative Neoplasms: Therapeutic and Genomic Considerations.
- Published in:
- Current Hematologic Malignancy Reports, 2018, v. 13, n. 6, p. 588, doi. 10.1007/s11899-018-0491-5
- By:
- Publication type:
- Article
Corticosteroid-induced morphological changes in cells of the myeloid lineage.
- Published in:
- American Journal of Hematology, 2015, v. 90, n. 7, p. 679, doi. 10.1002/ajh.23943
- By:
- Publication type:
- Article
Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey.
- Published in:
- 2017
- By:
- Publication type:
- journal article
The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes.
- Published in:
- Cancer (0008543X), 2022, v. 128, n. 14, p. 2717, doi. 10.1002/cncr.34222
- By:
- Publication type:
- Article